TSM Quantitative Stock Analysis

Validea's guru fundamental report assigns Taiwan Semiconductor Manufacturing Co. Ltd. (TSM) a strong 91% rating under Peter Lynch's P/E/Growth Investor model, which targets large-cap growth stocks with reasonable valuations relative to earnings growth and robust balance sheets. TSM demonstrated strength across critical metrics including P/E/Growth, EPS growth, and debt/equity ratios, indicating significant interest from this value-oriented growth strategy within the Semiconductor industry.

Analysis

Taiwan Semiconductor Manufacturing Co. (TSM) has received a highly favorable quantitative rating of 91% based on Validea's model of Peter Lynch's P/E/Growth investment strategy, indicating a strong alignment with criteria for reasonably priced growth stocks. As a large-cap stock in the Semiconductors industry, TSM successfully passed key tests for its P/E/Growth ratio, Sales to P/E ratio, Inventory to Sales, EPS Growth Rate, and Total Debt/Equity ratio. This combination suggests the company exhibits attractive earnings growth relative to its valuation and maintains a strong balance sheet. However, the analysis also flagged neutral ratings for Free Cash Flow and Net Cash Position, indicating that while many fundamental aspects are robust, its performance on these specific cash-related metrics is not a standout strength according to the model's parameters. The overall assessment is strongly positive, reinforcing TSM's profile as a fundamentally sound growth investment.

Key Decisions for Investors

• Investors with a Growth at a Reasonable Price (GARP) focus should consider this 91% rating on a Lynch-based model as a significant positive data point, warranting a closer look at TSM for potential inclusion in a portfolio.
• While the report highlights strong fundamentals, the neutral ratings on Free Cash Flow and Net Cash Position suggest these specific areas require further due diligence before committing new capital.
• For existing holders, this analysis provides strong validation of the company's fundamental health, particularly its earnings growth and balance sheet management, justifying a continued hold position pending any changes to these key metrics.